Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit
- PMID: 20561034
- PMCID: PMC2970906
- DOI: 10.1111/j.1600-0609.2010.01491.x
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit
Abstract
Objectives: Cardiac complications because of transfusional iron overload are the main cause of death in thalassaemia major. New chelators and iron monitoring methods such as cardiac magnetic resonance (CMR) became available after the year 2000. We evaluated the impact of these new management options on cardiac mortality and morbidity.
Methods: The risk of cardiac death during 1990-1999 and 2000-2008 was compared. Furthermore, after 1999, morbidity, mortality and reversal of heart failure were evaluated according to chelation regime: desferrioxamine (DFO), deferiprone (DFP) and combination therapy of DFO and DFP. We also present preliminary results for deferasirox (DFX), a new oral chelator.
Results: Three hundred and fifty-four patients were included in the de novo cardiac event evaluation, while 86 were included in the improvement component. The annual risk of cardiac death in patients aged between 20-30 and 30-40 reduced from 1.52% to 0.67% and 1.87% to 0.56%, respectively, before and after the year 2000. The risk for a de novo cardiac event for DFO was 9.1 times greater than that of DFP and 23.6 than with the combination of DFP and DFO. For DFX, there was one cardiac event over 269 patient-years. The risk of cardiac death was 9.5 per 1000 patient-years for DFO, 2.5 on DFP, 1.4 on combination. In the DFX group no cardiac deaths were recorded. The odds of improvement were 8.5 times greater with DFP and 6.1 with combination therapy compared to DFO.
Conclusions: The new chelation regimes, together with CMR have contributed significantly to the reduction in cardiac morbidity and mortality in patients with thalassaemia major.
© 2010 John Wiley & Sons A/S.
Figures


Similar articles
-
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.PLoS One. 2013 Dec 23;8(12):e82662. doi: 10.1371/journal.pone.0082662. eCollection 2013. PLoS One. 2013. PMID: 24376563 Free PMC article.
-
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28. Pediatr Blood Cancer. 2015. PMID: 25820920
-
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.Expert Rev Clin Pharmacol. 2018 Jun;11(6):641-650. doi: 10.1080/17512433.2018.1473760. Epub 2018 May 18. Expert Rev Clin Pharmacol. 2018. PMID: 29727586 Review.
-
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.Eur J Haematol. 2015 Nov;95(5):411-20. doi: 10.1111/ejh.12507. Epub 2015 Mar 27. Eur J Haematol. 2015. PMID: 25600572 Clinical Trial.
-
Recent developments in iron chelation therapy.Klin Padiatr. 2007 May-Jun;219(3):158-65. doi: 10.1055/s-2007-973845. Klin Padiatr. 2007. PMID: 17525910 Review.
Cited by
-
Gene Therapy: A Revolutionary Step in Treating Thalassemia.Hematol Rep. 2024 Oct 21;16(4):656-668. doi: 10.3390/hematolrep16040064. Hematol Rep. 2024. PMID: 39449307 Free PMC article. Review.
-
Treating thalassemia major-related iron overload: the role of deferiprone.J Blood Med. 2012;3:119-29. doi: 10.2147/JBM.S27400. Epub 2012 Oct 19. J Blood Med. 2012. PMID: 23112580 Free PMC article.
-
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.Pharmacoeconomics. 2013 Sep;31(9):807-22. doi: 10.1007/s40273-013-0076-z. Pharmacoeconomics. 2013. PMID: 23868464 Free PMC article.
-
In search of the optimal iron chelation therapy for patients with thalassemia major.Haematologica. 2011 Jan;96(1):5-8. doi: 10.3324/haematol.2010.034397. Haematologica. 2011. PMID: 21193427 Free PMC article. No abstract available.
-
Effect of HBB genotype on survival in a cohort of transfusion-dependent thalassemia patients in Cyprus.Haematologica. 2021 Sep 1;106(9):2458-2468. doi: 10.3324/haematol.2020.260224. Haematologica. 2021. PMID: 32732363 Free PMC article.
References
-
- Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2. - PubMed
-
- Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93. - PubMed
-
- Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445–50. - PubMed
-
- Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol. 2009;82:381–7. - PubMed
-
- Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107:150–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical